High Court Ruling Speeds Up Generic Biotech Drug Approval

High Court Ruling Speeds Up Generic Biotech Drug Approval
AP Photo/Andrew Harnik, File

A unanimous Supreme Court is speeding up the time for generic biotech drugs to become available to the public in a ruling that means a loss of billions in sales to the makers of original versions.

The justices ruled Monday in favor of generic drug maker Sandoz in its dispute with rival Amgen over a near-copy of Amgen's cancer drug Neupogen.



Comment
Show comments Hide Comments


Related Articles